Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
George D. Yancopoulos, M.D., Ph.D. is recorded as Chairman at Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. reported in an 8-K filed April 17, 2023 that George D. Yancopoulos, M.D., Ph.D. was appointed Co-Chair of the Board. George D. Yancopoulos, M.D., Ph.D. has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Regeneron Pharmaceuticals, Inc. on June 12, 2026.
“Effective upon the expiration of Dr. Vagelos’s term, the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board (in addition to Dr. Schleifer’s and Dr. Yancopoulos’s continued roles as President and Chief Executive Officer and President and Chief Scientific Officer, respectively) and to designate Christine A. Poon as the Lead Independent Director of the Board.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2023-04-17–present
Recorded roles and call appearances connecting this person to public companies.
Chairman
2023-04-17–present
Other people whose current roles at this company are on record from its filings.
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
